SCHEMBL24754832

SCHEMBL24754832

Cn1nc(-c2ccc(OCc3ccccc3)nc2OCc2ccccc2)c2cccc(NCC(=O)N3CCN(C(=O)OC(C)(C)C)CC3)c21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TLR9 Q9NR96 4/20 0.40
▸ ACHE P22303 2/20 0.40
▸ TLR7 Q9NYK1 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CCNT1 O60563 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CCNA1 P78396 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ SLC2A1 P11166 1/20 0.37
▸ PRMT5 O14744 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ DTYMK P23919 2/20 0.36
▸ CKS1B P61024 2/20 0.36
▸ SKP1 P63208 2/20 0.36
▸ SKP2 Q13309 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30029738 1.00 TLR9 (0.40) TLR9ACHETLR7MEN1KMT2A
SCHEMBL30794148 0.87 JAK2 (0.44) CCNT1CDK9PRMT5
SCHEMBL30794238 0.87 JAK2 (0.44) CCNT1CDK9PRMT5
SCHEMBL26636825 0.87 TLR9 (0.44) TLR9ACHETLR7MEN1KMT2A
SCHEMBL24754190 0.86 CCNT1 (0.41) TLR9ACHETLR7MEN1KMT2A
SCHEMBL30029433 0.86 CCNT1 (0.41) TLR9ACHETLR7MEN1KMT2A
SCHEMBL30706118 0.86 HTR6 (0.46) PRMT5
SCHEMBL30705958 0.86 HTR6 (0.46) PRMT5
SCHEMBL30705933 0.84 HTR6 (0.44) PRMT5
SCHEMBL30705889 0.83 PRMT5 (0.46) MEN1KMT2APRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022266248-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2022-12-22 — — WO disclosed
Send feedback